Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
Fig 3
Kaplan-Meier curves for progression-free survival (A) in the entire cohort, (B) in activated mutation, (C) in EGFR and ALK-negative/unknown groups, respectively. EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, d-PFS progression-free days.